ClinicalTrials.gg
CompletedNCT00080210Updated Jun 3, 2013

A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy

A Phase 2 interventional study of Puricase in Gout, sponsored by Savient Pharmaceuticals. Completed at 9 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-06-03.

Sponsored by Savient Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
9th of 14
40 · median 93
Started
2004
with 1 other
Phase 2
3 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
4 of 14
Savient Pharmaceuticals

Among the 14 studies testing pegloticase in Gout, this one is the 9th largest by enrollment, is one of 2 that started in 2004, is one of 3 in phase 2, and was the 1st registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous doses of Puricase, administered intravenously, in 40 patients with symptomatic gout. Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and must refrain from using such agents throughout the study.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • elevated uric acid
  • Elevated serum uric acid level
  • Symptomatic gout
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects to be included in the study are:

  • Outpatients of either gender, age 18 or older
  • Diagnosed with symptomatic gout to conventional therapy or unable to tolerate conventional therapy (for example: having one or more tophi and/or having experienced a gout flare within the previous 6 months and/or having chronic, gouty arthritis)
  • Hyperuricemic: screening serum uric acid must be >=8 mg/dL.
  • The patient must be willing and able to give and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed)
  • Women of must have a negative serum pregnancy test and must use an approved method during their participation in the protocol. Such methods include oral, injectable, or implantable contraceptives; IUDs and barrier contraceptives in combination with spermicide

Exclusion criteria

Exclusion Criteria:

Subjects to be excluded are those for whom any of the following apply:

  • Unstable coronary artery disease or uncontrolled hypertension
  • History of end stage renal disease requiring dialysis
  • History of liver disease, as defined by baseline serum transaminase elevation >3X the in the absence of any other known cause
  • Organ transplant recipient requiring therapy
  • Concurrent use of prednisone at a dose >10 mg qd (or equivalent) at or within one week before dosing
  • Concurrent use of uric acid-lowering agents
  • Prior treatment with Puricase® or other recombinant uricase
  • An acute gout flare within one week prior to first treatment with Puricase® (exclusive of chronic synovitis/arthritis) requiring use of medication which violates the protocol
  • glucose-6-phosphate dehydrogenase deficiency
  • A history of anaphylactic reaction to a recombinant protein or porcine derivatives
  • Lactation
  • Has taken an drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
  • Known allergy to urate oxidase or PEGylated products
  • Has any other medical or psychological condition which, in the opinion of the investigator, might create undue risk to the patient or interfere with the patient's ability to comply with the protocol requirements
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants

Interventions

06

Study locations

9 sites
  • Spain Rehabilitation Center
    Birmingham, Alabama 35294, United States
  • University of California, San Diego
    La Jolla, California 92037, United States
  • University of Chicago Dept of Medicine
    Chicago, Illinois 60637, United States
  • Graves Gilbert Clinic
    Bowling Green, Kentucky 42101, United States
  • Center for Rheumatology and Bone Research
    Wheaton, Maryland 20902, United States
  • North Shore University Hospital Division of Rheumatology
    Manhasset, New York 11030, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Oregon Health & Science University Arthritis & Rheumatic Diseases
    Portland, Oregon 97239, United States
  • Pride Clinical research Associates
    Pittsburgh, Pennsylvania 15219, United States
07

References and documents

Publications

  • Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z; Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep;58(9):2882-91. doi: 10.1002/art.23810. PubMed 18759308 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2004
First posted
Mar 25, 2004
Start
Mar 2004
Completion
Feb 2005
Last update
Jun 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jun 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00080210
Lead sponsor
Savient Pharmaceuticals
First posted
Mar 25, 2004
Start date
Mar 2004
Completion
Feb 2005
Last update
Jun 3, 2013
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegloticase

Start the discussion